Salmeterol Efficacy and Bias in the Activation and Kinase-Mediated Desensitization of β2-Adrenergic Receptors
- 1 June 2015
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 87 (6) , 954-964
Abstract
Salmeterol is a long-acting β2-adrenergic receptor (β2AR) agonist that is widely used as a bronchodilator for the treatment of persistent asthma and chronic obstructive pulmonary disease in conjunction with steroids. Previous studies demonstrated that salmeterol showed weak efficacy for activation of adenylyl cyclase; however, its efficacy in the complex desensitization of the β2AR remains poorly understood. In this work, we provide insights into the roles played by the G protein–coupled receptor kinase/arrestin and protein kinase A in salmeterol-mediated desensitization through bioluminescence resonance energy transfer (BRET) studies of liganded-β2AR binding to arrestin and through kinetic studies of cAMP turnover. First, BRET demonstrated a much reduced efficacy for salmeterol recruitment of arrestin to β2AR relative to isoproterenol. The ratio of BRETISO/BRETSALM after 5-minute stimulation was 20 and decreased to 5 after 35 minutes, reflecting a progressive decline in BRETISO and a stable BRETSALM. Second, to assess salmeterol efficacy for functional desensitization, we examined the kinetics of salmeterol-induced cAMP accumulation (0–30 minutes) in human airway smooth muscle cells in the presence and absence of phosphodiesterase inhibition. Analysis of shaping of cAMP turnover for both agonists demonstrated significant salmeterol desensitization, although it was reduced relative to isoproterenol. Using an isoproterenol rescue protocol after either short-term (10 minutes) or long-term (2 and 14 hours) salmeterol pretreatments, we found that salmeterol progressively depressed isoproterenol stimulation but did not prevent subsequent rescue by isoproterenol and additional isoproterenol-mediated desensitization. Our findings reveal a complex efficacy for functional desensitization, demonstrating that although salmeterol shows weak efficacy for adenylyl cyclase activation and G protein–coupled receptor kinase/arrestin-mediated desensitization, it acts as a strong agonist in highly amplified protein kinase A–mediated events.Keywords
This publication has 54 references indexed in Scilit:
- β 2 -Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoidsProceedings of the National Academy of Sciences, 2011
- Formoterol and salmeterol induce a similar degree of β2‐adrenoceptor tolerance in human small airways but via different mechanismsBritish Journal of Pharmacology, 2011
- Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting β2-adrenoceptor agonist exposureJournal of Allergy and Clinical Immunology, 2010
- Molecular mechanisms for the persistent bronchodilatory effect of the β2‐adrenoceptor agonist salmeterolBritish Journal of Pharmacology, 2009
- An estimation of β2‐adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilatorsBritish Journal of Pharmacology, 2009
- Agonist‐specific patterns of β2‐adrenoceptor responses in human airway cells during prolonged exposureBritish Journal of Pharmacology, 2009
- Roles of GRK and PDE4 Activities in the Regulation of β2 Adrenergic SignalingJournal of General Physiology, 2008
- β‐Arrestins specifically constrain β2‐adrenergic receptor signaling and function in airway smooth muscleThe FASEB Journal, 2008
- Crystal Structures of the Luciferase and Green Fluorescent Protein from Renilla reniformisJournal of Molecular Biology, 2007
- A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applicationsNature Biotechnology, 2002